Rituximab Trumps Natalizumab in MS Relapse
A drug used to treat patients with multiple sclerosis could improve their relapse rates, according to a new study in the Journal of Experimental Psychiatry and Infectious Diseases (IARC) in Northern Ireland, and the British Medical Journal (BMJ).
Source: medscape.comPublished on 2021-12-03
Related news
- Project Liberty the plan to replace Facebook
- Move over , Facebook : social media reform is on the way - and it may involve blockchain
- AstraZeneca to supply the US government with an additional one million doses of EVUSHELD long - acting antibody combination for the prevention of COVID - 19
- APEC Healthcare Webinar Focuses on Aging Population , Pandemic , and AI Solutions for Smart Medical Care
- Smart Powers First Digital Dinagyang Festival , Supporting Customer Needs in Pandemic Starmometer
- Euopean VC firm announces the final close of its 30M Fund II to help CEE - based startups grow
- Industry Payments Linked With Rheumatologist Prescribing
- European Innovation Council Fund : first equity investments of 178 million in breakthrough innovations
- Patient Safety Movement Foundation Welcomes New Leadership
- Patient Safety Movement Foundation Welcomes New Leadership
- A US Propaganda Operation Hit Russia and China With Memes
- AllGov - Officials
- European Innovation Council Fund : first equity investments of 178 million in breakthrough innovations | EU Commission Press
- Time for laws to catch up with economy
- Coronavirus Roundup : Vaccines Are Being Offered to Afghanistan Evacuees ; New HHS Office Launches